| Name | Title | Contact Details |
|---|
Comp-U-charge is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Have a Heart`s core mission is to provide the medical, psychological and social benefits of one of the world`s oldest and safest medicines to those in need and to those looking for a safer alternative to alcohol and prescription and illicit drugs. Our goal is to do this in a manner that is innovative, legal and compliant and that provides the most wonderful experience for our guests, our employees and the community overall. We focus on improving the local aesthetic, reducing crime and providing employment to those seeking legitimate employment in the cannabis industry. We believe in providing our customers with the highest quality product in a comfortable, professional and safe environment. All of our locations are unique and have been designed for the comfort and entertainment of our customer. Our friendly and knowledgeable team is always willing to answer any questions, so you`ll find the correct product for your needs. At Have a Heart we have taken many steps to ensure that our customers feel the trust and passion for excellence they deserve.
Segetis, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac`s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac`s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA.
Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn`s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials.